NEW YORK, May 10, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ: NLNK). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at firstname.lastname@example.org or 212-697-6484.
The investigation concerns whether NewLink and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On Monday, May 9, 2016, NewLink's phase III study disclosed that its experimental cancer vaccine, known as algenpantucel-L, which was designed to stimulate a patient's immune system to recognize and kill cancer cells, did not actually do so and failed to prolong survival in patients with pancreatic cancer compared to a standard therapy. Following this news, on Monday, May 9, 2016 post market, NewLink stock dropped as much as $10.69 per share, or 38.48%.
If you are aware of any facts relating to this investigation, or purchased shares of NewLink, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/#!nlnk/omiv7. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-newlink-genetics-corporation-nlnk-300265921.html
SOURCE Bronstein, Gewirtz & Grossman, LLC